Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide in lymphatic fluid transport
NCT05683444Phase 1Completed
- Sponsor
- Rigshospitalet
- Start
- Jul 2020
- Primary completion
- Mar 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Octreotide long-acting injection in chylothorax and lymphatic diseases, sponsored by Rigshospitalet. Primary endpoints: Lymph rate at 2.5 hours, Lymph Pressure at 2.5 hours and 1 more. Started Jul 2020; status: completed.
02
Drugs
Octreotide long-acting injection
03
Conditions
chylothoraxlymphatic diseases
Beyond the preview
Go deeper on NCT05683444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683444.